Lowering systemic inflammation reduces pain and improves movement, multiplying the health benefits of these medications
According to the UK SmPC for Wegovy, fatigue is classified as a 'common' side effect (affecting between 1 in 10 and 1 in 100 people)
The exact frequency depends on factors like body weight, treatment goals, and medical advice
Researchers should consult the research peptides legal status guide and the FDA peptide reclassification overview for current compliance context when designing protocols involving either compound
According to the 2024 American Diabetes Association Standards of Care, GLP-1 receptor agonists have become first line pharmacotherapy for most patients with type 2 diabetes mellitus (T2DM), including those with concomitant atherosclerotic cardiovascular disease (ASCVD), indicators of high ASCVD risk, or chronic kidney disease